We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 16, 2020

Single-Agent Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma

Blood Cancer Journal


Additional Info

Blood Cancer Journal
Single-Agent Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma: Analysis of the Lyophilised Presentation Cohort From the Pivotal DREAMM-2 Study
Blood Cancer J 2020 Oct 23;[EPub Ahead of Print], PG Richardson, HC Lee, AO Abdallah, AD Cohen, P Kapoor, PM Voorhees, A Hoos, K Wang, J Baron, T Piontek, J Byrne, S Richmond, RC Jewell, J Opalinska, I Gupta, S Lonial

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading